רווח תפעולי לפני פחת: Iterum Therapeutics plc (ITRM)

The investment potential of Iterum Therapeutics plc (ITRM) is based on the high margins of proprietary antibiotics coupled with minimal production costs. The absolute EBITDA volume clearly demonstrates the dynamics of this scaling. The company's strategy relies on the expansion of Orlynvq within the US B2B sector, while the anticipation of new regulatory approvals creates powerful growth catalysts, with the 0.00 metric serving as the target level.

This indicator captures the actual cash flow generated by core operations before depreciation and interest, reflecting the business's capacity for self-financing. As Iterum Therapeutics plc (ITRM) competes for the antibiotic market and defends its FDA patents, analyzing the EBITDA metric allows for an assessment of how well operating cash flow covers R&D expenses, confirming the company's fundamental stability.